Stock Events

Stock Events

LadRx 

$5.05
3
-$0.15-2.88% Wednesday 19:08

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

28MarExpected
Q1 2022
Q2 2022
Q3 2022
Q1 2024
Q2 2024
Q3 2024
Q4 2024
-0.04
-0.03
-0.03
-0.02
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-4.76MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LADXD. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company that competes with LadRx in the development and marketing of medications across various therapeutic areas.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a leading pharmaceutical company that offers innovative health solutions and vaccines, competing directly with LadRx's product lines.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is a diversified healthcare giant that competes with LadRx in pharmaceuticals, including drugs and treatments for various conditions.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in the pharmaceutical industry, focusing on immunology, oncology, and virology, areas where LadRx also aims to innovate.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that competes with LadRx in the development of treatments for life-threatening diseases, including HIV and hepatitis.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotechnology firm focusing on human therapeutics, competing with LadRx in areas such as oncology and cardiovascular disease.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a global biopharmaceutical company, competing with LadRx in the discovery, development, and delivery of medicines for cancer and other diseases.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that competes with LadRx in providing healthcare solutions and innovative medicines in various therapeutic areas.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a leader in research-focused healthcare with strengths in pharmaceuticals and diagnostics, competing with LadRx in multiple therapeutic areas.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a global, science-led biopharmaceutical business that competes with LadRx in developing and commercializing prescription medicines across several sectors.

About

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
Show more...
CEO
ISIN
US2328287071

Listings

OTC Link
US
LADX
LSE
GB
0I5R.LSE

0 Comments

Share your thoughts

FAQ

What is LadRx stock price today?▼
The current price of LADXD is $5.05 USD — it has decreased by -2.88% in the past 24 hours. Watch LadRx stock price performance more closely on the chart.
What is LadRx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange LadRx stocks are traded under the ticker LADXD.
What is LadRx revenue for the last year?▼
LadRx revenue for the last year amounts to 0 USD.
What is LadRx net income for the last year?▼
LADXD net income for the last year is -4.76M USD.
When did LadRx complete a stock split?▼
The last stock split for LadRx was on May 18, 2023 with a ratio of 1:100.